EQS-News
109 
0 Kommentare
Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
- Pentixapharm to report Q3 and 9M results on Nov 12.
- Conference call at 3 PM CET for business update.
- Focus on innovative radiopharmaceuticals in oncology.
|
EQS-News: Pentixapharm Holding AG / Key word(s): 9 Month figures/Quarterly / Interim Statement
Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results |
Berlin, Germany, November 10, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, will publish its financial results for the third quarter and first nine months of 2025 on Wednesday, November 12, 2025.
Management will host a conference call and webcast on the same day to discuss the quarterly results and provide a business update.
Conference Call and Webcast Details
Date: Wednesday, November 12, 2025
Time: 3 p.m. CET / 9:00 a.m. EST
Registration link to participate in the conference call:
https://webcast.meetyoo.de/reg/BXIDSCew5bUU
Live webcast link:
https://www.webcast-eqs.com/pentixapharm-202511
Presentation slides will be posted shortly before the start of the webcast at the Investor Relations section of the Pentixapharm website. A replay of the webcast will be available at this website shortly after the event.
About Pentixapharm
Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops first-in-class ligand- and antibody-based radiopharmaceuticals designed to transform patient care across oncology and beyond. Its late-stage pipeline is anchored by CXCR4-targeted programs, including a Phase 3-ready diagnostic candidate for primary aldosteronism and pioneering therapeutic programs in a number of hematological and solid cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-escape marker over-expressed in multiple hard-to-treat cancers. Complemented by reliable isotope supply from Eckert & Ziegler, and a robust global clinical network, Pentixapharm is uniquely positioned to deliver innovative radiopharmaceuticals that address high unmet need, improve patient outcomes, and create significant growth opportunities in one of the fastest-growing areas of precision medicine.
Pentixapharm Investor and Media Contact
10.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content:
EQS News
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2226488 |
| End of News | EQS News Service |
|
|
2226488 10.11.2025 CET/CEST
Diskutieren Sie über die enthaltenen Werte
URL kopieren
Per E-Mail teilen
Artikel drucken